Belite Bio (BLTE) Net Income towards Common Stockholders (2022 - 2026)
Belite Bio's (BLTE) quarterly Net Income towards Common Stockholders came in at -$0.68 in Q1 2026, down 251.11% year-on-year from $0.45 in Q1 2025, and down 197.14% quarter-over-quarter from $0.7 in Q4 2025.
Belite Bio (BLTE) Net Income towards Common Stockholders (2022 - 2026) Analysis & Trends
Belite Bio's Net Income towards Common Stockholders history runs 5 years deep, the most recent figure standing at -$0.68 for Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders fell 251.11% year-over-year to -$0.68 in Q1 2026; TTM through Mar 2026 was $0.17, a 77.03% decrease from a year earlier, with the FY2025 full-year figure at $2.31, up 95.76% from the prior year.
- Net Income towards Common Stockholders declined to -$0.68 in Q1 2026 per BLTE's latest filing, from $0.7 in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $0.7 in Q4 2025 and bottomed at -$0.68 in Q1 2026.
- The 5-year median for Net Income towards Common Stockholders is $0.27 (2022), against an average of $0.12.
- Biggest YoY gain for Net Income towards Common Stockholders was 300.0% in 2023; the steepest drop was 316.67% in 2023.
- Year by year, Net Income towards Common Stockholders stood at $0.27 in 2022, then slumped by 192.59% to -$0.25 in 2023, then jumped by 228.0% to $0.32 in 2024, then jumped by 118.75% to $0.7 in 2025, then tumbled by 197.14% to -$0.68 in 2026.
- Per Business Quant, the three latest BLTE Net Income towards Common Stockholders figures stand at -$0.68 (Q1 2026), $0.7 (Q4 2025), and $0.65 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.68 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 366.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 205.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.68 |
| Dec 31, 2025 | 0.70 |
| Sep 30, 2025 | 0.65 |
| Jun 30, 2025 | -0.50 |
| Mar 31, 2025 | 0.45 |
| Dec 31, 2024 | 0.32 |
| Sep 30, 2024 | 0.28 |
| Jun 30, 2024 | -0.31 |
| Mar 31, 2024 | 0.27 |
| Dec 31, 2023 | -0.25 |
| Sep 30, 2023 | 0.40 |
| Jun 30, 2023 | -0.26 |
| Mar 31, 2023 | 0.33 |
| Dec 31, 2022 | 0.27 |
| Sep 30, 2022 | 0.10 |
| Jun 30, 2022 | 0.12 |